BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37311352)

  • 1. Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect.
    Kumar Gupta S; Gohil D; Dutta D; Panigrahi GC; Gupta P; Dalvi K; Khanka T; Yadav S; Kumar Kaushal R; Chichra A; Punatar S; Gokarn A; Mirgh S; Jindal N; Nayak L; Tembhare PR; Khizer Hasan S; Kumar Sandur S; Hingorani L; Khattry N; Gota V
    Int Immunopharmacol; 2023 Aug; 121():110437. PubMed ID: 37311352
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gupta SK; Gohil D; Momin MB; Yadav S; Chichra A; Punatar S; Gokarn A; Mirgh S; Jindal N; Nayak L; Hingorani L; Khattry N; Gota V
    Cell Transplant; 2024; 33():9636897241226573. PubMed ID: 38258793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of acute graft-versus-host-disease by Withaferin a via suppression of AKT/mTOR pathway.
    Mehta M; Gohil D; Khattry N; Kumar R; Sandur S; Sharma D; Checker R; Agarwal B; Jha D; Majumdar A; Gota V
    Int Immunopharmacol; 2020 Jul; 84():106575. PubMed ID: 32416453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Yao Y; Wang L; Zhou J; Zhang X
    J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models.
    Fowler KA; Li K; Whitehurst CB; Bruce DW; Moorman NJ; Aubé J; Coghill JM
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1062-1074. PubMed ID: 30668984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
    Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
    Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects.
    Liu Y; Wu Y; Wang Y; Cai Y; Hu B; Bao G; Fang H; Zhao L; Ma S; Cheng Q; Song Y; Liu Y; Zhu Z; Chang H; Yu X; Sun A; Zhang Y; Vignali DA; Wu D; Liu H
    Leukemia; 2015 Apr; 29(4):939-46. PubMed ID: 25363669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
    Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H
    Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R707, a fully human antibody directed against CC-chemokine receptor 7, attenuates xenogeneic acute graft-versus-host disease.
    Fowler KA; Vasilieva V; Ivanova E; Rimkevich O; Sokolov A; Abbasova S; Kim E; Coghill JM
    Am J Transplant; 2019 Jul; 19(7):1941-1954. PubMed ID: 30748092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
    Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAR1 improved Treg cell function through the miR-21b/Foxp3 axis and inhibits the progression of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Zhao Y; Zheng X; Li M; Zhao J; Wang X; Zhu H
    Int Immunopharmacol; 2023 Feb; 115():109620. PubMed ID: 36577155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.
    Delia M; Carluccio P; Mestice A; Chiusolo P; Metafuni E; Bellesi S; Arpinati M; Milone GA; Martino M; Mazza P; Ingrosso C; Vacca A; Saporiti G; Zallio F; Attolico I; Pastore D; Specchia G; Albano F; Musto P
    Transplant Cell Ther; 2021 Nov; 27(11):918.e1-918.e9. PubMed ID: 34403789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Caspase1 Inhibitor Ac-YVAD-CMK Prevents and Treats the Acute Graft Versus Host Disease in Mice].
    Kong QL; Chen W; Sun GZ; Cao J; Cheng H; Qi KM; Pan XY; Li ZY; Zeng LY; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):203-208. PubMed ID: 28245402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg.
    Yu M; Wang J; Fang Q; Liu P; Chen S; Zhe N; Lin X; Zhang Y; Zhao J; Zhou Z
    Transpl Immunol; 2016 Jul; 37():10-17. PubMed ID: 27168057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.